Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis

Rheumatology International

Volumn 32, Issue 1, 2012, Pages 145-150

  Kimura, Koji ^a   Takayanagi, Risa ^a   Yokoyama, Haruko ^a   Yamada, Yasuhiko ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Crohn's disease; Infliximab; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

INFLIXIMAB;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; COMPARTMENT MODEL; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TENDER JOINT COUNT; THEORETICAL MODEL; VALIDITY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JAPAN; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857113440     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1553-8     Document Type: Article

References (19)

1. M Kaneko T Tomita T Nakase Y Ohsawa H Seki E Takeuchi H Takano K Shi K Takahi E Kominami, et al. 2001 Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis Rheumatology (Oxford) 40 247 255 10.1093/rheumatology/40.3.247 1:CAS:528:DC%2BD3MXjtVOgt78%3D
2. M Feldmann FM Brennan RN Maini 1996 Role of cytokines in rheumatoid arthritis Annu Rev Immunol 14 397 440 10.1146/annurev.immunol.14.1.397 8717520 10.1146/annurev.immunol.14.1.397 1:CAS:528:DyaK28XitlCgtb4%3D (Pubitemid 26130190)
3. Imura Y (2008) Wakariyasui Naikagaku. bunkoudou, Tokyo
4. A Eigler B Sinha G Hartmann S Endres 1997 Taming TNF: strategies to restrain this proinflammatory cytokine Immunol Today 18 487 492 9357141 10.1016/S0167-5699(97)01118-3 1:CAS:528:DyaK2sXmvFentLo%3D (Pubitemid 27441592)
5. CP Braegger S Nicholls SH Murch S Stephens TT MacDonald 1992 Tumour necrosis factor alpha in stool as a marker of intestinal inflammation Lancet 339 89 91 1345871 10.1016/0140-6736(92)90999-J 1:STN:280:DyaK38%2FpvFOlsw%3D%3D
6. WR Garnett N Yunker 2001 Treatment of Crohn's disease with infliximab Am J Health Syst Pharm 58 307 316 11225167 1:CAS:528:DC%2BD3MXhsVCku7w%3D quiz 317-309
7. B Scallon A Cai N Solowski A Rosenberg XY Song D Shealy C Wagner 2002 Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 418 426 11961039 10.1124/jpet.301.2.418 1:CAS:528:DC%2BD38XjtlKjurw%3D (Pubitemid 34429950)
8. BJ Scallon MA Moore H Trinh DM Knight J Ghrayeb 1995 Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 251 259 10.1006/cyto.1995. 0029 7640345 10.1006/cyto.1995.0029 1:CAS:528:DyaK2MXls1ait70%3D
9. SA Siegel DJ Shealy MT Nakada J Le DS Woulfe L Probert G Kollias J Ghrayeb J Vilcek PE Daddona 1995 The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo Cytokine 7 15 25 10.1006/cyto.1995.1003 7538333 10.1006/cyto.1995.1003 1:CAS:528:DyaK2MXjs1ehtL0%3D
10. REMICADE for I.V. infusion100 (2007) Product Information
11. Y Furuya T Ozeki R Takayanagi H Yokoyama K Okuyama Y Yamada 2007 Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease Drug Metab Pharmacokinet 22 20 25 17329907 10.2133/dmpk.22.20 1:CAS:528: DC%2BD2sXksF2lur8%3D
12. RA Black CT Rauch CJ Kozlosky JJ Peschon JL Slack MF Wolfson BJ Castner KL Stocking P Reddy S Srinivasan, et al. 1997 A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 729 733 10.1038/385729a0 9034190 10.1038/385729a0 1:CAS:528:DyaK2sXhsVGktLs%3D (Pubitemid 27098094)
13. F Cornillie D Shealy G D'Haens K Geboes G Van Assche J Ceuppens C Wagner T Schaible SE Plevy SR Targan, et al. 2001 Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease Aliment Pharmacol Ther 15 463 473 11284774 10.1046/j.1365-2036.2001.00956.x 1:CAS:528:DC%2BD3MXjtVyis7w%3D (Pubitemid 32242771)
14. SB Hanauer BG Feagan GR Lichtenstein LF Mayer S Schreiber JF Colombel D Rachmilewitz DC Wolf A Olson W Bao, et al. 2002 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541 1549 10.1016/S0140-6736(02)08512-4 12047962 10.1016/S0140-6736(02)08512-4 1:CAS:528:DC%2BD38Xkt1Gru70%3D (Pubitemid 34621118)
15. DR Couriel K Hicks S Giralt RE Champlin 2000 Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation Curr Opin Oncol 12 582 587 11085458 10.1097/00001622- 200011000-00011 1:CAS:528:DC%2BD3cXos1ygtLo%3D (Pubitemid 32039658)
16. T Robak A Gladalska H Stepien 1998 The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis Eur Cytokine Netw 9 145 154 9681390 1:CAS:528:DyaK1cXkslGqsrY%3D (Pubitemid 28301573)
17. M Blick SA Sherwin M Rosenblum J Gutterman 1987 Phase I study of recombinant tumor necrosis factor in cancer patients Cancer Res 47 2986 2989 3567916 1:STN:280:DyaL2s7oslWruw%3D%3D (Pubitemid 17113448)
18. V Bocci 1991 Interleukins. Clinical pharmacokinetics and practical implications Clin Pharmacokinet 21 274 284 1760900 10.2165/00003088-199121040- 00004 1:CAS:528:DyaK38XhsV2mtLk%3D
19. Furusawa SIJ (1998) Laboratory hematology, 3rd edn. Igaku-Shoin, Tokyo